TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04775706: Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

Sponsor: Hanmi Pharmaceutical Company Limited · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,826,000

Rescue Site Savings

+$1,195,200

Unlock Full NCT04775706 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04775706 Rescue Dossier →